Drug Formulations
Research topic drug formulations uitklapper, klik om te openen
A drug is more than just an API (active pharmaceutical ingredient). The formulation of a drug product largely influences its efficacy by modulating the biological availability, pharmacokinetics and sometimes even metabolism of the drug substance. When there is a wish to treat patients with an active substance, this is based on the anticipated pharmacological effect at the target site. Market products have been designed to deliver compounds in this way. Furthermore, they have been clinically evaluated and hence there is data available on their efficacy. When a specific application is not commercially available, the drug product can be compounded within the hospital pharmacy. For a long time, this has been done by a lege artis approach, where aspects like appearance, producability and stability get often more attention than biopharmaceutical considerations. In line with the “Quality by Design” principles, it is our goal to develop drug products that exceed the level of “lege artis”. Since it is often not clear what the fundamental principles are behind observed phenomena, we combine product development with research into mechanisms involved. Preferably, a clinical evaluation is a part of the development.
Examples:
- the development of oil depots, where we study the behavior of depots in vivo and try to unraffle the mechanism of drug release.
- Development of extended oropharyngeal release of antibiotics
- Development of tacrolimus enemas to be used in patient who undergone a transplantation
- Development of sirolimus ointment to be used for patients with Tuberose Sclerose Complex
Principal Investigator uitklapper, klik om te openen
Prof. Dr. Herman Vromans
Researchers uitklapper, klik om te openen
Mr Raween Kalicharan, PhD student
